Last reviewed · How we verify
Dabigatran etexilate pellets — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Dabigatran etexilate pellets (Dabigatran etexilate pellets) — Boehringer Ingelheim.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Dabigatran etexilate pellets TARGET | Dabigatran etexilate pellets | Boehringer Ingelheim | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Dabigatran etexilate pellets CI watch — RSS
- Dabigatran etexilate pellets CI watch — Atom
- Dabigatran etexilate pellets CI watch — JSON
- Dabigatran etexilate pellets alone — RSS
Cite this brief
Drug Landscape (2026). Dabigatran etexilate pellets — Competitive Intelligence Brief. https://druglandscape.com/ci/dabigatran-etexilate-pellets. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing